Celgene dives 10% after ditching key drug By: MarketWatch October 20, 2017 at 11:31 AM EDT The once high-profile drug was expected to bring in as much as $2.4 billion in peak revenue. Read More >> Related Stocks: Celgene Corp Johnson & Johnson Standard & Poors 500